SS-31 (Elamipretide): The Mitochondrial Peptide Targeting Energy, Aging, and Cellular Repair

Mitochondrial dysfunction sits at the center of almost every age-related disease researchers study — from heart failure and neurodegeneration to metabolic syndrome and muscle wasting. For decades, the best tools available were indirect: antioxidant supplements, exercise interventions, and caloric restriction. SS-31 changed that. It’s the first peptide designed to go directly inside mitochondria and stabilize the membrane structures that keep them functioning.

Also known as elamipretide, SS-31 has something most research peptides lack: extensive human clinical trial data. Phase 2 and Phase 3 studies across heart failure, Barth syndrome, age-related macular degeneration, and mitochondrial myopathy make it arguably the most clinically validated peptide in the mitochondrial medicine space.

What Is SS-31 and How Does It Work?

SS-31 is a synthetic tetrapeptide with the sequence D-Arg-Dmt-Lys-Phe-NH2. The “SS” stands for Szeto-Schiller, named after the researchers who designed it. Two structural features make it unusual among peptides.

First, it uses D-arginine instead of L-arginine, which makes it resistant to enzymatic degradation. Most peptides are broken down within minutes in the bloodstream — SS-31 persists long enough to reach its target. Second, its alternating pattern of cationic (positively charged) and aromatic amino acids gives it a strong, selective affinity for cardiolipin.

Cardiolipin is a phospholipid found almost exclusively on the inner mitochondrial membrane. It’s essential for the structural integrity of the electron transport chain complexes and the formation of mitochondrial cristae — the folded membrane structures where ATP production occurs. When cardiolipin becomes oxidized or disorganized (as it does during aging, ischemia, and disease), electron transport becomes inefficient, ATP output drops, and reactive oxygen species (ROS) production increases.

SS-31 binds to cardiolipin and stabilizes its interaction with cytochrome c, preventing the peroxidase activity that damages the membrane. The result is restored electron transport efficiency, improved ATP synthesis, and reduced oxidative stress — not by scavenging free radicals after they’re produced, but by preventing their overproduction at the source.

Why SS-31 Is Different from Antioxidants and CoQ10

Researchers have tried targeting mitochondrial dysfunction with general antioxidants (vitamin C, vitamin E, NAC) and mitochondria-associated compounds (CoQ10, MitoQ) for years. The results have been consistently underwhelming in clinical settings. The reason is specificity.

General antioxidants distribute throughout the entire body and have no particular affinity for mitochondria. Even “mitochondria-targeted” compounds like MitoQ and SkQ1 rely on the mitochondrial membrane potential to accumulate inside the organelle, which means they become less effective precisely when mitochondria are most damaged and membrane potential is compromised.

SS-31 bypasses this problem entirely. Its cardiolipin-binding mechanism is independent of membrane potential. It concentrates approximately 5,000-fold inside mitochondria regardless of how damaged they are. This makes it effective in exactly the conditions where other approaches fail — ischemia-reperfusion injury, aged tissue, and diseased cells with collapsed membrane potential.

Clinical Trial Evidence

Barth Syndrome (FDA Approval)

In 2025, elamipretide received FDA accelerated approval for Barth syndrome under the brand name Forzinity. Barth syndrome is a rare genetic disorder caused by mutations in the tafazzin gene, which impairs cardiolipin remodeling. Patients experience cardiomyopathy, skeletal myopathy, and exercise intolerance. Clinical trials showed elamipretide improved six-minute walk test performance and cardiac function in these patients — directly validating the cardiolipin-stabilization mechanism in humans.

Heart Failure with Reduced Ejection Fraction (HFrEF)

The PROGRESS-HF Phase 2 trial evaluated elamipretide in patients with heart failure. While the primary endpoint (change in left ventricular end-systolic volume) did not reach statistical significance, secondary analyses showed improvements in cardiac biomarkers and patient-reported outcomes. The compound demonstrated excellent safety and tolerability, with injection site reactions as the most common adverse event.

Age-Related Macular Degeneration

The ReCLAIM studies investigated elamipretide for geographic atrophy secondary to dry AMD. Early results suggested stabilization of retinal structure and function, consistent with the hypothesis that mitochondrial dysfunction in retinal pigment epithelial cells drives photoreceptor degeneration.

Primary Mitochondrial Myopathy

The MMPOWER trials evaluated elamipretide in patients with genetically confirmed mitochondrial myopathy. Phase 2 results showed trends toward improved six-minute walk distance and reduced fatigue, though Phase 3 results were mixed.

SS-31 and Aging Research

Beyond specific diseases, SS-31 has generated significant interest as a tool for studying age-related mitochondrial decline. Preclinical studies in aged animals have demonstrated that SS-31 treatment can:

• Restore skeletal muscle mitochondrial energetics to near-youthful levels
• Improve exercise tolerance without increasing mitochondrial content (meaning it optimizes existing mitochondria rather than triggering biogenesis)
• Reduce age-related cardiac hypertrophy and diastolic dysfunction
• Restore redox homeostasis in aged kidney tissue
• Improve insulin sensitivity in skeletal muscle of aged models

These findings have made SS-31 a cornerstone compound for researchers investigating the “mitochondrial theory of aging” — the hypothesis that progressive mitochondrial dysfunction drives the biological aging process across multiple organ systems.

How SS-31 Compares to Other Mitochondrial Peptides

SS-31 isn’t the only peptide relevant to mitochondrial research, but it occupies a unique niche.

MOTS-c is a mitochondrial-derived peptide (encoded in mitochondrial DNA) that activates AMPK and improves glucose metabolism and exercise capacity. While MOTS-c works through metabolic signaling pathways, SS-31 works by directly stabilizing mitochondrial membrane architecture. They target different aspects of mitochondrial biology and may be complementary for researchers studying metabolic aging.

NAD+ supplementation supports mitochondrial function by maintaining the NAD+/NADH ratio critical for electron transport and sirtuin activity. NAD+ addresses the fuel supply side of mitochondrial function; SS-31 addresses the structural integrity of the machinery that uses that fuel.

SLU-PP-332 is an ERR (estrogen-related receptor) agonist that activates exercise-mimetic pathways including mitochondrial biogenesis. While SLU-PP-332 increases mitochondrial number, SS-31 improves the function of existing mitochondria — again suggesting complementary rather than overlapping mechanisms.

Pharmacokinetics and Stability

SS-31’s D-amino acid substitution gives it significantly better stability than most research peptides. Key pharmacokinetic parameters from clinical studies include:

• Bioavailability: approximately 100% via subcutaneous injection
• Half-life: approximately 2–4 hours in plasma
• Mitochondrial concentration: ~5,000-fold accumulation relative to plasma
• Metabolism: minimal hepatic metabolism due to D-amino acid resistance to proteases

For research purposes, the rapid mitochondrial uptake means that tissue-level effects begin quickly even though plasma half-life is relatively short. Studies have shown sustained functional improvements lasting well beyond the plasma elimination window, consistent with the hypothesis that cardiolipin stabilization has durable downstream effects on mitochondrial structure.

Research Applications and Open Questions

Active areas of SS-31 research in 2026 include:

Ischemia-reperfusion injury: SS-31 has shown protective effects in cardiac, renal, and cerebral ischemia-reperfusion models. The mechanism — preventing cardiolipin peroxidation during reperfusion — is well-characterized and has potential implications for organ transplantation and stroke research.

Exercise physiology: Preclinical data showing improved exercise tolerance without increased mitochondrial biogenesis raises interesting questions about whether mitochondrial efficiency (output per organelle) can be pharmacologically enhanced independently of mitochondrial quantity.

Neurodegenerative disease: Mitochondrial dysfunction is a hallmark of Parkinson’s, Alzheimer’s, and ALS. Early preclinical work with SS-31 in neurodegenerative models has shown protective effects, though no human trials in these indications have been completed.

Metabolic disease: The connection between mitochondrial dysfunction, insulin resistance, and metabolic syndrome makes SS-31 relevant to obesity and diabetes research — particularly in combination with compounds like MOTS-c that target metabolic signaling.

Key Takeaways

SS-31 represents a genuinely novel approach to mitochondrial medicine. Rather than scavenging free radicals or boosting cofactor levels, it goes directly to the inner mitochondrial membrane and stabilizes the structural foundation of cellular energy production. With FDA approval for Barth syndrome and clinical trials across multiple indications, it has more human safety and efficacy data than almost any other research peptide in its class.

For researchers studying mitochondrial dysfunction — whether in aging, heart disease, neurodegeneration, or metabolic disease — SS-31 offers a precision tool that addresses the root cause rather than downstream symptoms.

All products mentioned in this article are sold strictly for research purposes only. SS-31 and all peptides available through Prax Peptides are not intended for human consumption. Always consult applicable regulations and institutional guidelines before designing research protocols.